

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 2003/102019 A3

(51) International Patent Classification⁷: C12Q 1/68, C12P
19/34, C12N 15/63, C07H 21/02, 21/04, A01N 43/04

(21) International Application Number:
PCT/US2003/017638

(22) International Filing Date: 4 June 2003 (04.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/161,996 4 June 2002 (04.06.2002) US

(71) Applicant (for all designated States except US): ISIS
PHARMACEUTICALS, INC. [US/US]; 2292 Faraday
Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FRIER, Susan,
M. [US/US]; 2946 Renault Street, San Diego, CA 92122
(US). BAKER, Brenda, F. [US/US]; 2147 Avenida
Toronja, Carlsbad, CA 92009 (US). DOBIE, Kenneth, W.
[GB/US]; 703 Stratford Ct., #4, Del Mar, CA 92014 (US).

(74) Agent: COZEN O'CONNOR P.C.; 1900 Market Street,
Philadelphia, PA 19103 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
4 March 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.



WO 2003/102019 A3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/17638

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12P 19/34; C12N 15/63; C07H 21/02, 21/04; A01N 43/04
US CL : 435/6, 91.1, 91.31, 455; 514/44; 536/23.1, 24.5
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.1, 91.31, 455; 514/44; 536/23.1, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

West, Dialog

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YOKOYAMA et al. SREBP-1, a basic helix loop helix leucine zipper protein that controls transcription of the low density lipoprotein receptor gene, Cell. 08 October 1993, Vol. 75, pages 187-197, 1993, see especially figure 1, page 188, text in left column, page 194.	1-14
Y	MILNER, N. et al. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotech. June 1997, Vol. 15, pages 537-541, 1997, see entire document, esp. pages 538-539.	1-14
Y	US 5,877,309 A (McKAY et al) 02 March 1999, see especially col. 6-13.	3-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 08 SEPTEMBER 2003	Date of mailing of the international search report 03 DEC 2003
--	--

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
Jane Lara
Telephone No. (703) 308-0196